Sinan Guloksuz1, Baer Arts2, Sharon Walter2, Marjan Drukker2, Laura Rodriguez2, Aye-Mu Myint3, Markus J Schwarz4, Rudolf Ponds2, Jim van Os5, Gunter Kenis2, Bart P F Rutten6. 1. Department of Psychiatry and Neuropsychology, Maastricht University Medical Centre, EURON, School for Mental Health and Neuroscience, Maastricht, The Netherlands; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. 2. Department of Psychiatry and Neuropsychology, Maastricht University Medical Centre, EURON, School for Mental Health and Neuroscience, Maastricht, The Netherlands. 3. Department of Psychiatry and Neuropsychology, Maastricht University Medical Centre, EURON, School for Mental Health and Neuroscience, Maastricht, The Netherlands; University Hospital, Ludwig Maximilian University, Munich, Germany. 4. University Hospital, Ludwig Maximilian University, Munich, Germany. 5. Department of Psychiatry and Neuropsychology, Maastricht University Medical Centre, EURON, School for Mental Health and Neuroscience, Maastricht, The Netherlands; King's College London, King's Health Partners, Department of Psychosis Studies, Institute of Psychiatry, London, United Kingdom. 6. Department of Psychiatry and Neuropsychology, Maastricht University Medical Centre, EURON, School for Mental Health and Neuroscience, Maastricht, The Netherlands. Electronic address: b.rutten@maastrichtuniversity.nl.
Abstract
BACKGROUND: There is still limited knowledge about the mechanism of action of electroconvulsive therapy (ECT) in the treatment of depression. Substantial evidence suggests a role for the immune-moderated tryptophan (TRP)-kynurenine (KYN) pathway in depression; i.e. a depression-associated disturbance in the balance between the TRP-KYN metabolites towards a neurotoxic process. We, therefore, aimed to investigate the impact of ECT treatment on the TRP-KYN pathway, in association with ECT-related alterations in depressive symptoms. METHOD: Twenty-three patients with unipolar or bipolar depression, treated with bilateral ECT twice a week were recruited. Blood serum samples, and depression scores using the Hamilton Depression Rating Scale-17 items (HDRS) as well as the Beck Depression Inventory (BDI) were collected repeatedly during the period of ECT and until 6 weeks after the last ECT session. TRP and KYN metabolites were analyzed in serum using the High Performance Liquid Chromatography. Four patients could not complete the study; thereby yielding data of 19 patients. Analyses were performed using multilevel linear regression analysis. RESULTS: There was an increase in kynurenic acid (KYNA) (B=0.04, p=0.001), KYN/TRP ratio (B=0.14, p=0.001), KYNA/KYN ratio (B=0.07, p<0.0001), and KYNA/3-hydroxykynurenine ratio (B=0.01, p=0.008) over time during the study period. KYN (B=-0.02, p=0.003) and KYN/TRP (B=-0.19, p=0.003) were negatively associated with total HDRS over time. Baseline TRP metabolite concentrations did not predict time to ECT response. CONCLUSION: Our findings show that ECT influences the TRP-KYN pathway, with a shift in TRP-KYN metabolites balance towards molecules with neuroprotective properties correlating with antidepressant effects of ECT; thereby providing a first line of evidence that the mechanism of action of ECT is (co)mediated by the TRP-KYN pathway.
BACKGROUND: There is still limited knowledge about the mechanism of action of electroconvulsive therapy (ECT) in the treatment of depression. Substantial evidence suggests a role for the immune-moderated tryptophan (TRP)-kynurenine (KYN) pathway in depression; i.e. a depression-associated disturbance in the balance between the TRP-KYN metabolites towards a neurotoxic process. We, therefore, aimed to investigate the impact of ECT treatment on the TRP-KYN pathway, in association with ECT-related alterations in depressive symptoms. METHOD: Twenty-three patients with unipolar or bipolar depression, treated with bilateral ECT twice a week were recruited. Blood serum samples, and depression scores using the Hamilton Depression Rating Scale-17 items (HDRS) as well as the Beck Depression Inventory (BDI) were collected repeatedly during the period of ECT and until 6 weeks after the last ECT session. TRP and KYN metabolites were analyzed in serum using the High Performance Liquid Chromatography. Four patients could not complete the study; thereby yielding data of 19 patients. Analyses were performed using multilevel linear regression analysis. RESULTS: There was an increase in kynurenic acid (KYNA) (B=0.04, p=0.001), KYN/TRP ratio (B=0.14, p=0.001), KYNA/KYN ratio (B=0.07, p<0.0001), and KYNA/3-hydroxykynurenine ratio (B=0.01, p=0.008) over time during the study period. KYN (B=-0.02, p=0.003) and KYN/TRP (B=-0.19, p=0.003) were negatively associated with total HDRS over time. Baseline TRP metabolite concentrations did not predict time to ECT response. CONCLUSION: Our findings show that ECT influences the TRP-KYN pathway, with a shift in TRP-KYN metabolites balance towards molecules with neuroprotective properties correlating with antidepressant effects of ECT; thereby providing a first line of evidence that the mechanism of action of ECT is (co)mediated by the TRP-KYN pathway.
Authors: Hyong Jin Cho; Jonathan Savitz; Robert Dantzer; T Kent Teague; Wayne C Drevets; Michael R Irwin Journal: J Psychosom Res Date: 2017-05-22 Impact factor: 3.006
Authors: Jonathan Savitz; Bart N Ford; Rayus Kuplicki; Sahib Khalsa; T Kent Teague; Martin P Paulus Journal: Psychopharmacology (Berl) Date: 2022-10-22 Impact factor: 4.415
Authors: Lilly Schwieler; Martin Samuelsson; Mark A Frye; Maria Bhat; Ina Schuppe-Koistinen; Oscar Jungholm; Anette G Johansson; Mikael Landén; Carl M Sellgren; Sophie Erhardt Journal: J Neuroinflammation Date: 2016-02-29 Impact factor: 8.322
Authors: Annamari Sorri; Kaija Järventausta; Olli Kampman; Kai Lehtimäki; Minna Björkqvist; Kati Tuohimaa; Mari Hämäläinen; Eeva Moilanen; Esa Leinonen Journal: Brain Behav Date: 2018-02-22 Impact factor: 2.708
Authors: Eva Z Reininghaus; Nina Dalkner; Karin Riedrich; Dietmar Fuchs; Johanna M Gostner; Bernd Reininghaus Journal: Front Psychiatry Date: 2019-02-21 Impact factor: 4.157
Authors: Johann Steiner; Henrik Dobrowolny; Paul C Guest; Hans-Gert Bernstein; Dietmar Fuchs; Julien Roeser; Paul Summergrad; Gregory F Oxenkrug Journal: Int J Tryptophan Res Date: 2021-05-19